Group 1 - Vanke A announced the sale of 22 million A-share treasury stocks for a total of 146 million yuan, representing 0.18% of the company's total share capital, aimed at supplementing liquidity without impacting current profits [1] - Tencent Music plans to acquire 100% of Himalaya for a total consideration of $1.26 billion, which includes cash and shares, to expand its audio content ecosystem [1] - Dongfang Electric Heat signed a strategic cooperation agreement with Xiaomi's subsidiary to develop robotic electronic skin, focusing on flexible fabric pressure sensing applications [3] Group 2 - Chengdu Huamei launched a 4-channel, 12-bit, 16G high-precision RF direct sampling ADC chip, marking a significant breakthrough in high-speed data conversion technology [4] - Jinshi Technology clarified that it has not engaged in any business related to stablecoins, despite recent market interest, and noted a significant stock price increase of 76.51% over six trading days [5] - Xiantan Co. reported a 14.22% year-on-year increase in chicken product sales revenue for May, amounting to 469 million yuan [7]

证券代码：688136 证券简称：科兴制药 公告编号：2025-035 科兴生物制药股份有限公司 关于转让全资子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）拟将持有 的全资子公司深圳同安医药有限公司（以下简称"同安医药"或"标的公司"）100% 的股权转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研所"）， 转让价格为1,500.00万元。 本次交易不构成关联交易，也不构成《上市公司重大资产重组管理办法》 规定的重大资产重组，且交易实施不存在重大法律障碍。 本次交易已经公司第二届董事会第二十五次会议审议通过，无需提交股 东大会审议。 一、交易概述 根据公司的整体经营规划，为进一步聚焦生物医药主赛道，降低管理成本， 提高资产运营效率，公司于2025年6月9日召开第二届董事会第二十五次会议、第 二届监事会第二十一次会议审议通过《关于转让全资子公司股权的议案》，公司 拟将持有的全资子公司同安医药100%的股权转让给广西药研所。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-034 科兴生物制药股份有限公司 第二届监事会第二十一次会议决议公告 2025 年 6 月 11 日 科兴生物制药股份有限公司（以下简称"公司"）第二届监事会第二十一 次会议于 2025 年 6 月 9 日以现场的方式召开。会议通知已于 2025 年 6 月 6 日发 出。本次会议应出席监事 3 人，实际出席监事 3 人。 会议由监事会主席江海燕主持。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于转让全资子公司股权的议案》 公司监事会认为：考虑到公司全资子公司深圳同安医药有限公司（以下简称 "同安医药"）近年来未实际开展业务，将公司持有的同安医药 100%的股权作 价 1,500 万元转让给广西壮族自治区药物研究所有限公司（以下简称"广西药研 所"），有助于提高资产运营效率，符合公司的实际情况。本次交易定价合理， 审议程序合规，不存在损害股东尤其是中小股东利益的情况。同意公司本次将同 安医药 100%股权转让给广西药研所的事项。 表决结果：3 票同意，0 票反对，0 票弃权。 特此公告。 科 ...

Core Viewpoint - The animal vaccine sector has shown a positive performance with a 1.29% increase, ranking 10th among concept sectors, driven by significant gains in stocks like *ST Xianfeng, Kexing Pharmaceutical, and Jinhai Biological [1][2]. Group 1: Sector Performance - As of June 10, the animal vaccine concept saw 16 stocks rise, with *ST Xianfeng hitting the daily limit, while Kexing Pharmaceutical and Jinhai Biological increased by 6.40% and 4.72% respectively [1]. - The sector's performance is part of a broader market trend, with various other concepts also experiencing fluctuations, such as the transgenic sector rising by 3.15% [2]. Group 2: Capital Flow - The animal vaccine sector attracted a net inflow of 150 million yuan, with 10 stocks receiving significant capital inflows, and 7 stocks exceeding 10 million yuan in net inflow [2]. - Jinhai Biological led the net inflow with 67.34 million yuan, followed by Kexing Pharmaceutical and Dabeinong with 36.46 million yuan and 21.42 million yuan respectively [2][3]. Group 3: Stock-Specific Data - The top stocks by net capital inflow ratio included *ST Xianfeng at 10.73%, Kexing Pharmaceutical at 9.86%, and Jinhai Biological at 8.93% [3]. - The trading volume and turnover rates for key stocks indicate active trading, with Jinhai Biological showing a turnover rate of 15.46% and Kexing Pharmaceutical at 3.35% [3].

Core Insights - The recombinant protein sector saw a rise of 1.42%, ranking 8th among concept sectors, with 26 stocks increasing in value, including Sai Sheng Pharmaceutical which hit a 20% limit up [1] - Major gainers in the sector included Jie Ya Co., Yi Pin Hong, and Zhong Yuan He He, with increases of 14.83%, 9.40%, and 6.85% respectively [1] - The sector experienced a net outflow of 223 million yuan in capital, with 13 stocks receiving net inflows, and 10 stocks exceeding 10 million yuan in net inflows [2] Stock Performance - Sai Sheng Pharmaceutical led the net inflow with 165 million yuan, followed by Zhong Yuan He He, Ke Xing Pharmaceutical, and Yi Pin Hong with net inflows of 62.43 million yuan, 36.45 million yuan, and 28.04 million yuan respectively [2][3] - The top stocks by net inflow ratio included Sai Sheng Pharmaceutical at 23.69%, *ST Su Wu at 11.75%, and Ke Xing Pharmaceutical at 9.86% [3] Market Trends - The recombinant protein sector's performance was contrasted by other sectors, with the transgenic sector leading with a 3.15% increase, while EDR concept saw a decline of 2.63% [2] - The overall market sentiment reflected a mixed performance across various sectors, indicating selective investor interest [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Market Overview - The Shanghai Composite Index closed at 3403.52 points, above the five-day moving average, with a slight increase of 0.11% [1] - The total trading volume of A-shares reached 808.39 billion yuan [1] Stocks Performance - A total of 253 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Shuguang Digital (14.08% deviation) - Sun Cable (8.01% deviation) - Suqian Liansheng (7.42% deviation) [1] Top Gainers - The top gainers today include: - Shuguang Digital: 22.27% increase, latest price at 61.87 yuan - Sun Cable: 10.00% increase, latest price at 6.82 yuan - Suqian Liansheng: 10.00% increase, latest price at 9.90 yuan [1] Additional Notable Stocks - Other stocks with notable performance: - Celery Medical: 9.97% increase, latest price at 13.46 yuan - Zhongke Shuguang: 10.00% increase, latest price at 68.09 yuan - Yuanwang Valley: 9.97% increase, latest price at 7.28 yuan [1]

Core Viewpoint - The announcement of a share reduction by the controlling shareholder of Kexing Pharmaceutical has raised concerns in the market, leading to a significant drop in the company's stock price following the news [2][3]. Group 1: Share Reduction Announcement - Kexing Pharmaceutical's controlling shareholder, Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., plans to reduce its holdings by up to 5.9892 million shares [2]. - The controlling shareholder, Keyi Pharmaceutical, has not sold any shares since the company's IPO, and the shares being reduced were acquired before the IPO [3]. - The reason for the reduction is to optimize the company's shareholding structure and increase liquidity in the secondary market, although the market has expressed skepticism regarding this rationale [2][3]. Group 2: Stock Performance and Market Reaction - Following the announcement, Kexing Pharmaceutical's stock price fell by 8.51% on June 5, marking one of the largest declines in a month [2]. - The stock price had previously surged from around 20 yuan at the beginning of the year to a high of 63.99 yuan, reflecting a significant increase of over 150% since the IPO price of 22.33 yuan [3][8]. Group 3: Company Response and Future Outlook - Kexing Pharmaceutical maintains that the controlling shareholder has confidence in the company's future and plans to increase holdings in 2023 and 2024 [4]. - The company emphasizes its commitment to innovation and internationalization as part of its long-term strategy to enhance shareholder value [4][8]. - Kexing Pharmaceutical reported a revenue of 1.4 billion yuan in 2024, with a year-on-year growth of 11.75%, and a net profit of 31.48 million yuan, indicating a turnaround from previous losses [9][10].

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced significant fluctuations, with a cumulative closing price deviation exceeding 30% over three trading days, prompting a notice of abnormal trading [1][2]. The company emphasizes that its innovative drug projects are still in the preclinical stage, indicating uncertainty in future progress [2]. Group 1: Company Performance and Financials - Kexing Pharmaceutical is primarily engaged in the research, production, and sales of recombinant protein drugs and microbiome preparations, focusing on antiviral, hematology, oncology, immunology, and degenerative diseases [3]. - The company reported a significant decline in profits post-IPO, with net profits dropping from 1.39 billion yuan in 2020 to a loss of 902.95 million yuan in 2022. However, in 2024, it achieved a revenue of 1.407 billion yuan, a year-on-year increase of 11.75%, and a net profit of 31.48 million yuan, marking a return to profitability [4]. - Kexing currently has six proprietary products on the market and has introduced 16 products in key disease areas such as oncology and diabetes [5]. Group 2: Research and Development - The company has ten innovative drug projects in development, with nine still in the preclinical stage, highlighting the uncertainty in the R&D pipeline [6]. - R&D investment for 2024 was reported at 199 million yuan, a decrease of 42.31% year-on-year, with the proportion of R&D investment to revenue dropping from 27.39% in 2023 to 14.14% [6]. - The number of R&D personnel decreased from 208 in 2022 to 138 in 2024, indicating a significant reduction in workforce [7]. - Kexing is actively pursuing internationalization and aims to complete a certain number of clinical submissions for innovative drugs in the US and China each year, while also enhancing its business development capabilities [8].

证券代码：688136 证券简称：科兴制药 公告编号：2025-033 科兴生物制药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 ? 每股分配比例 每股现金红利0.08元（含税） （1）差异化分红方案 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配方 案的议案》，公司拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证 券账户中股份为基数分配利润，拟向全体股东每 10 股派发现金红利 0.80 元（含税）。 公司不进行公积金转增股本，不送红股。如自 2025 年 3 月 31 日之日起至实施权 益分派股权登记日期间，公司总股本扣减公司回购专用证券账户中股份这一基数 发生变动的，公司拟维持每股分配比例不变，相应调整分配总额。 截至本公告披露日，公司总股本为 199,642,250 股，扣除回购专户的股份数 股东每 10 股派发现金股利 0.8 元（含税），本次将派发现金红利 15,778,506.0 ...